Report Publication Announcement • Jan 8, 2016
Report Publication Announcement
Open in ViewerOpens in native device viewer
Strasbourg, France, January 8, 2016 - Transgene SA (Euronext: TNG) today announced its financial reporting dates for 2016:
| March 8: | 2015 Fiscal Year Results |
|---|---|
| April 21: | First Quarter 2016 Financial Results |
| May 24: | Annual Shareholders' Meeting |
| September 5: | First Half 2016 Financial Results |
| October 20: | Third Quarter 2016 Financial Results |
Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.
Elisabetta Castelli, Director Investor Relations Raimund Gabriel +33 (0)3 88 27 91 21 +49 89 210 228 30
Laurie Doyle, Director Investor Relations US & Corporate Communications +1 (339) 832 0752 Shaun Brown
+44 207 148 5998 [email protected] [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.